Call it What You Like
This article was originally published in Start Up
Executive Summary
Nuveen announced in September that it began selling a new biotechnology sector fund for retail investors. But only one of the fifteen stocks in the fixed portfolio has a market cap below $2 billion. If money is starting to flow into the biotech sector, Nuveen is still taking no chances with small-caps.